Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Jul 6, 2010

Premium

Nick Naclerio has become senior vice president of corporate development at Illumina. He will be responsible for all corporate and business development activities, including licensing, strategic planning, and acquisitions. Prior to Illumina, Naclerio was the executive chairman of Quanterix, which he co-founded. Previously, he was executive chairman of True Materials and president and CEO of ParAllele BioScience, both of which were later sold to Affymetrix. Naclerio holds a PhD in electrical engineering from the University of Maryland.


Douglas White has become CEO of OpGen, taking over from Evan Jones, who had held the position on an interim basis and will remain on OpGen's board of directors. Prior to joining the firm, White was executive vice president and general manager for the diagnostics division of BG Medicine. Before that, he was chairman of the Americas management council and senior vice president of sales and marketing for the Americas at Qiagen. White holds a BA in political science from Washington College.


Fred Walder has joined Fluidigm as chief business officer. Most recently, he was senior vice president of customer and commercial excellence at Thermo Fisher Scientific, where he previously held various senior operating roles. Walder holds a BS in chemistry from the University of Massachusetts.


Yemi Adesokan is the co-founder and CEO of startup Pathogenica (see article, this issue). Previously, he was a postdoctoral fellow with George Church at Harvard Medical School. Adesokan holds a PhD in theoretical chemistry from the University of California, Irvine, and a BS in biology from the University of Houston.

Graeme Doran is Pathogenica's chief scientific officer. Before, he was a postdoctoral scientist at the David H. Koch Center for Integrative Cancer Research at the Massachusetts Institute of Technology and at the department of pathology at Harvard Medical School. Graeme holds a PhD in genetic epidemiology and molecular biology of human neurological disorders as well as an undergraduate degree from the University of Oxford.

Bill Cook is the company's vice president of regulatory affairs. Previously, he was vice president of strategy and business development for the global molecular diagnostics program at Affymetrix and Applied Imaging. He also held management roles at DiaDexus, Chiron, Ciba Corning, Shell Oil’s Triton Biosciences, and Beckman Coulter. Cook holds an MBA in international marketing from National University, San Diego, and a BS in microbiology from California State University, San Diego.

Sabrina Haas is Pathogenica's director of medical affairs. She is also the director of the antimicrobial stewardship program at Beverly Hospital in Beverly, Mass. Previously, she worked for the New York City Department of Health's Bureau of Tuberculosis Control. Haas holds an MD and a BA in human biology from the University of Kansas.

John Boyce
and Jessica Tonani are in charge of business development at Pathogenica. Both are co-founders of consulting firm Delphi Bio. Boyce was most recently head of business development for Helicos BioSciences. Previously, he was senior director of commercial development for ParAllele Bioscience, and prior to that, director for US sales and marketing at Sequenom. Tonani previously held senior positions at Affymetrix and Sequenom. At Affymetrix, she was most recently associate director of DNA product marketing.


Andre Marion has joined the scientific advisory board of WaferGen. Until 1995, he was president of the Applied Biosystems division of Perkin-Elmer. Previously, he was president and CEO of Applied Biosystems, which he co-founded. Prior to that, he held various research and development managerial positions at Hewlett-Packard. Marion holds a degree in both mechanical and electronic engineering from École Nationale Supérieure d'Arts et Métiers in France.


William Shanahan has retired from the board of directors of Life Technologies to have time to pursue other matters. He will continue to consult for the company. Shanahan had been a member of the board since 2008.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.